• Subject or subject's LAR has provided informed consent.

• ≥18 years of age.

• If the patient were to receive MT, patient must have a history of last seen well ≤ 24 hours prior to start of MT

• If the patient were to receive IVT, patient must have a history of last seen well ≤ 4.5 hours prior to start of IVT or as per Institution SOC Note: Onset is defined as the time point when symptoms first began, or if unknown, the last time point when the subject reported or was observed having normal (baseline) neurological function.

• AIS patient with ASPECTS ≥ 3 to 10

• AIS patient with life expectancy of 90 days, as determined by the investigator

• Patient with disabling stroke defined as baseline NIHSS ≥ 6 prior to IP administration

• mRS ≤ 2 (pre-morbid), prior to onset of symptoms (self-reported or family/caregiver reported)

• At the time of stroke, patient must be living in their own home, apartment or seniors lodge where no nursing care/support is required

⁃ Subject and caregiver are available for protocol-required follow-up visits

⁃ Contraception and pregnancy:

• Male subjects, and females of childbearing potential (subjects and female partners of male subjects who are ovulating, premenopausal, and not surgically sterile) must use a highly effective method of contraception consistently and correctly during study participation and up to 90 days following PP-007 infusion.

∙ Highly effective methods of contraception are those that, either alone or in combination, result in a failure rate of \<1% per year when used consistently and correctly, including:

⁃ i. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (i.e., oral, intravaginal, or transdermal).

⁃ ii. Progesterone-only hormonal contraception associated with inhibition of ovulation (i.e., oral, injectable, or implantable).

⁃ iii. Intrauterine device, intrauterine hormone-releasing system, or bilateral tubal occlusion.

⁃ iv. Male sterilization performed more than six months prior to Screening. v. Sexual abstinence. c. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or postmenopausal, defined as spontaneous amenorrhea for at least 12 months.

⁃ d. Male subjects must abstain from sperm donation during study participation and up to 90 days following PP-007 infusion.

⁃ e. Female subjects of childbearing potential must have negative results for the pregnancy test at Screening/Baseline.

‣ AIS patient with ASPECTS ≥ 3 to 10